Search

Aurinia Pharmaceuticals Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

16.01 -0.37

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

16.01

Max

16.16

Pagrindiniai rodikliai

By Trading Economics

Pajamos

3.1M

37M

Pardavimai

5.5M

83M

P/E

Sektoriaus vid.

7.053

56.597

Pelnas, tenkantis vienai akcijai

0.28

Pelno marža

44.958

Darbuotojai

128

EBITDA

4.8M

55M

Dividendai

By Acuity

Kitas uždarbis

2026-11-03

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

266M

2.1B

Ankstesnė atidarymo kaina

16.38

Ankstesnė uždarymo kaina

16.01

Naujienos nuotaikos

By Acuity

50%

50%

136 / 339 reitingas Healthcare

Aurinia Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-09-10 20:06; UTC

Aurinia Pharmaceuticals shares are lower today, influenced by broader market declines amid macroeconomic factors, including the European Central Bank's interest rate hike.

2026-09-09 20:41; UTC

Aurinia Pharmaceuticals Inc shares are higher in after-market trading, showing increased investor interest despite no specific company news, remaining above their 20-day moving average.

2026-09-08 23:36; UTC

Aurinia Pharmaceuticals Inc is trading lower in after-market hours, with no specific news identified to explain the movement. The stock remains within its one-month trading range.

2026-09-01 20:08; UTC

Aurinia Pharmaceuticals is declining amid broader market losses and rising inflation concerns, with no specific company news identified to explain the movement.

2026-08-26 20:08; UTC

News

Aurinia Pharmaceuticals shares are lower amid broader Biotechnology sector weakness. A Form 4 filing revealed a $355,000 insider share sale by Chief Legal Officer Stephen P. Robertson.

2026-08-25 19:36; UTC

Aurinia Pharmaceuticals Inc is trading higher amid a positive market environment, despite pulling back from earlier session highs. No specific news was identified.

2026-08-24 22:01; UTC

Aurinia Pharmaceuticals Inc shares are lower in after-market hours, continuing a trend of declines observed over the past three sessions. No specific news was identified.

2026-08-21 23:06; UTC

Aurinia Pharmaceuticals Inc. shares are higher in after-market hours, reflecting routine trading activity and maintaining a position above the 20-day moving average.

2026-08-20 21:46; UTC

Aurinia Pharmaceuticals Inc shares are trading lower in after-market hours. No specific news was identified to explain the decline.

2026-08-19 23:02; UTC

News

Aurinia Pharmaceuticals settled patent litigation with Teva, securing exclusivity for voclosporin until December 2036. Shares rose in after-hours trading following the announcement.

2026-08-18 19:56; UTC

Aurinia Pharmaceuticals Inc is trading higher today, though no specific news has been identified. Rising Treasury yields may pose challenges for equities.

2026-08-17 20:02; UTC

Social Media

Aurinia Pharmaceuticals shares are lower amid broader market declines and rising crude oil prices, despite some social media chatter about potential buyout interest.

2026-08-14 19:26; UTC

Aurinia Pharmaceuticals shares are higher today, rebounding after earlier volatility amid broader market concerns over disappointing U.S. retail sales figures.

2026-08-13 19:56; UTC

News

Aurinia Pharmaceuticals shares are lower today, despite ongoing sales growth of Lupkynis and a recent acquisition of Kezar Life Sciences.

2026-08-11 20:06; UTC

Aurinia Pharmaceuticals Inc shares are trading lower today, continuing a trend of three consecutive daily declines amid no specific news to explain the movement.

2026-08-10 20:06; UTC

News

Aurinia Pharmaceuticals shares decline following multiple downgrades from research firms, despite Royal Bank of Canada raising its price target to $16.00.

2026-08-07 19:16; UTC

News

Aurinia Pharmaceuticals shares are lower today, despite earlier gains. RBC Capital raised the price target to $16.00 from $15.00, maintaining a Sector Perform rating.

2026-08-06 20:02; UTC

Event
News

Aurinia Pharmaceuticals reported second-quarter EPS of $0.28, exceeding estimates. The stock is higher today amid strong financial results and reaffirmed revenue guidance for 2026.

2026-08-04 19:46; UTC

Aurinia Pharmaceuticals Inc is trading higher amid a positive market environment and a decline in crude oil prices, which may benefit consumer spending.

2026-08-03 22:01; UTC

Aurinia Pharmaceuticals shares are higher in after-market hours, despite being below the 20-day moving average and three prior lower daily closes.

2026-08-01 00:01; UTC

Aurinia Pharmaceuticals Inc is trading lower in after-market hours, reflecting a significant decline in the overall market and ongoing weakness in performance metrics.

2026-07-31 21:01; UTC

Aurinia Pharmaceuticals Inc is higher in after-market trading, rising notably from a flat start. The stock remains below its 20-day moving average.

2026-07-30 20:31; UTC

Aurinia Pharmaceuticals Inc. shares rose in after-market trading, following a broader market trend as the S&P 500 also gained. No specific news was identified.

2026-07-29 22:01; UTC

Aurinia Pharmaceuticals Inc shares are lower in after-market hours, showing notable weakness and trading below its 20-day moving average. No specific news was identified.

2026-07-28 19:36; UTC

Aurinia Pharmaceuticals shares are lower, reflecting volatility amid broader market conditions. The stock is trading significantly below its 20-day moving average.

2026-07-27 19:16; UTC

Aurinia Pharmaceuticals is trading higher, benefiting from lower oil prices and easing inflation concerns ahead of the Federal Reserve meeting later this week.

2026-07-24 18:26; UTC

Aurinia Pharmaceuticals is trading higher, despite pulling back from earlier gains. Broader market volatility, influenced by declining oil prices, impacts sentiment.

2026-07-22 19:46; UTC

Aurinia Pharmaceuticals shares are lower today, continuing a decline since Tuesday's close. The stock is near its one-month trading range's lower end.

2026-07-21 19:16; UTC

Aurinia Pharmaceuticals is higher today, supported by a broader market uptick as investor interest in AI-related stocks grows ahead of major tech earnings.

2026-07-20 20:01; UTC

Aurinia Pharmaceuticals is lower today, reflecting broader market declines amid geopolitical tensions and oil price fluctuations. The stock hit a session low earlier.

Akcijų palyginimas

Kainos pokytis

Aurinia Pharmaceuticals Inc Prognozė

Bendras įvertinimas

By TipRanks

Vidutinis pirkimas

3 ratings

2

Pirkti

1

Laikyti

0

Parduoti

Rinkos nuotaikos

By Acuity

136 / 339 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.
help-icon Live chat